Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 183-190

  Choy, Gavin ^a   Joshi Hangal, Rajashree ^a   Oganesian, Aram ^a   Fine, Gil ^a   Rasmussen, Scott ^b   Collier, Joanne ^c   Kissling, James ^d   Sahai, Amarpal ^a   Azab, Mohammad ^a   Redkar, Sanjeev ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b CELERION   (United States)

^c Quotient Clinical Ltd   (United Kingdom)

^d MDS Inc   (Canada)

Author keywords

Amuvatinib; Food effect; MP 470; Pharmacokinetics; Phase 1

Indexed keywords

AMUVATINIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTCOME ASSESSMENT; POWDER; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSPENSION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CAPSULES; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HEADACHE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; YOUNG ADULT;

EID: 84863442871     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1821-2     Document Type: Article

References (18)

1. Qi W, Cooke LS, Stejskal A, Riley C, Della Croce K, Saldanha JW, Bearss D, Mahadevan D (2009) MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 9:142. doi:10.1186/1471-2407-9-142
2. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D (2007) A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26:3909-3919. doi:10.1038/sj.onc.1210173 (Pubitemid 46884299)
3. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4:69. doi:10. 1186/1748-717X-4-69
4. Zhao H, Luoto KR, Meng AX, Bristow RG (2011) The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. doi:10.1016/j.radonc. 2011.08.013 (Epub ahead of print)
5. Taverna P, Huang L, Choy G, Azab M (2010) Amuvatinib (MP- 470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts. In: 2010 EORTC-NCI-AACR proceedings Abstract 171
6. Morgan SS, Wang ZJ, Taverna P, Cranmer LD (2010) Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines. In: 2010 EORTC-NCI-AACR proceedings Abstract 193
7. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93(1):137-143. doi:10.1038/sj.bjc.6602665 (Pubitemid 41076262)
8. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105(4):472-479. doi:10.1002/ ijc.11106
9. Henning W, Sturzbecher HW (2003) Homologous recombination and cell cycle checkpoints: Rad51 in tumor progression and therapy resistance. Toxicology 193(1-2):91-109. doi:10.1016/S0300-483X(03)00291-9
10. Tolcher AW, Choy G, Joshi R, Redkar S, Fine G, Tibes R (2010) MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRa) and DNA repair protein Rad 51-final results from a first-in-man single agent study. In: 2010 AACR proceedings Abstract 2749
11. Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow R, Fine G, Choy GS, Azab M (2011) Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm Phase 1b trial in combination with 5 Standard of Care (SOC) anticancer regimens. In: 2011 ASCO proceedings Abstract 3074
12. Scholes PD, McDermott J, Vertommen J, Colin J-L, Choy G, Azab M, Joshi R, Redkar S (2010) Addressing the challenges of poor solubility: rapid development and clinical evaluation of a lipid based formulation to enhance oral bioavailability of amuvatinib (MP-470). In: 2010 AAPS proceedings Abstract R6077
13. Kissling CJ, Fine GD, Choy GS, Eddy C, Berk GI (2008) Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules. Eur J Cancer 6(12):134 (suppl; abstr 426). doi:10.1016/ S1359-6349(08)72360-7
14. Joshi R, Tang C, Inloes R, Shi C, Geddes D, Collier J, Rodriguez S, Mittan A, McLaughlin H, Fine G, Redkar S, Choy G (2009) A self-emulsifying lipid suspension formulation enhances oral bio-availability of MP-470 in a randomized two way crossover study in healthy male subjects. Mol Cancer Ther 8:12 (supp1; abstr B209). doi:10.1158/1535-7163.TARG-09-B209
15. Amidon GL, Lennernäs H, Shah VP, Crison J (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420. doi:10.1023/A:1016212804288
16. Porter CJ, Trevaskis NL, Charman WN (2007) Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6(3):231-248. doi:10.1038/nrd2197 (Pubitemid 46344627)
17. Jain RK, Brar SS, Lesko LJ (2010) Food and oral antineoplastics: more than meets the eye. Clin Cancer Res 16:4305-4307. doi:10.1158/1078-0432.CCR-10- 1857
18. Kang SP, Ratain MJ (2010) Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 16:4446-4451. doi:10.1158/1078-0432.CCR-10-0663